Key result
Continuing aspirin shows similar VTE rates to LMWH after total joint arthroplasty.
Why the study?
Optimum venous thromboembolism prophylaxis for patients undergoing total hip or knee arthroplasty remained undefined, prompting a comparison of complication rates between low-dose aspirin and low-molecular-weight heparin.
Does continuing low-dose aspirin (75 mg once daily) compared to low-molecular-weight heparin (dalteparin 5000 U) affect venous thromboembolism and complication rates in patients undergoing total hip or knee arthroplasty?
Observational (n=6,094)
Does continuing low-dose aspirin (75 mg once daily) compared to low-molecular-weight heparin (dalteparin 5000 U) affect venous thromboembolism and complication rates in patients undergoing total hip or knee arthroplasty?
Continuing chronic low-dose aspirin (75 mg daily) alone for VTE prophylaxis after total hip or knee arthroplasty yields similarly low VTE and complication rates compared to LMWH, despite patients on aspirin being older with more comorbidities.
Answers are grounded in this paper and cite their sources.
May support aspirin continuation for VTE prophylaxis post-arthroplasty in comorbid patients; leaves open need for randomized confirmation before practice change.
BACKGROUND: Optimum venous thromboembolism (VTE) prophylaxis for patients undergoing total hip or knee arthroplasty remains undefined. The purpose of this study is to compare complication rates among total joint arthroplasty patients using either low-dose aspirin (75 mg once daily) or low-molecular-weight heparin (LMWH; Fragmin/dalteparin 5000 U) for VTE prophylaxis. METHODS: This is a prospective observational study. All total hip or knee arthroplasties from 2014 to 2020 were included. One thousand eighty-four patients already taking aspirin 75 mg as primary or secondary prophylaxis for cardiovascular disease continued their daily aspirin dose throughout their hospital stay and after discharge without any other kind of thromboprophylaxis. Five thousand ten patients not already taking aspirin were given LMWH for 12-14 days starting the day of surgery. Both groups consisted of patients undergoing either primary or revision total hip or knee arthroplasty. The aspirin group was older (73 ± 7.8 vs 66 ± 10.2 years, P < .01, 95% CI -7.6, -6.3) with more comorbidities but otherwise did not differ from the LMWH group. Outcome measures were recorded at 3-month follow-up and included the following complications: clinically deep venous thrombosis (DVT), pulmonary embolism (PE), deep infection, blood transfusion, and death. RESULTS: The aspirin group had 0.28% DVT and 0.28% PE, and the LMWH group had 0.24% DVT and 0.16% PE (P = .42 and .74, respectively). No difference in deep infection, allogenic blood transfusion, or mortality was found. CONCLUSION: No statistically significant difference in complication rates was found between aspirin 75 mg and LMWH used for VTE prophylaxis. Aspirin 75 mg daily is safe for VTE prophylaxis after total hip or knee arthroplasty.
No takes yet. Share an insight, caveat, or question.
Høvik et al. (2021) conducted an observational in Total hip or knee arthroplasty (n=6,094). Aspirin vs. Low-molecular-weight heparin (dalteparin 5000 U) for 12-14 days was evaluated on Clinically deep venous thrombosis (DVT) (p=0.42). Continuing aspirin daily resulted in similar rates of DVT and PE compared to LMWH after total joint arthroplasty.
Synapse has enriched 10 related papers. Consider them for comparative context: